Objective Low molecular weight heparin (LMWH) is currently the most commonly used intravenous anticoagulant drugs, but the lack of point of care testing (POCT) limit its applications in patients with severe renal dysfunction and others. The purpose of this study was to explore the sensitivity of new activated clotting time (ACT) reagents for laboratory monitoring of LMWH.
第一作者机构：[1]Beijing Tong Ren Hosp, Dept Cardiol, Beijing, Peoples R China
推荐引用方式(GB/T 7714)：
Shi Xu-Bo,Hu Da-Yi,Wang Ji-Yun,et al.THE SENSITIVITY OF NEW REAGENTS FOR LABORATORY MONITORING OF LOW MOLECULAR WEIGHT HEPARIN: AN IN VITRO STUDY[J].HEART.2010,96:A55-A55.doi:10.1136/hrt.2010.208967.171.
APA：
Shi Xu-Bo,Hu Da-Yi,Wang Ji-Yun,Hou Xiao-Xia&Ma Zhi-Min.(2010).THE SENSITIVITY OF NEW REAGENTS FOR LABORATORY MONITORING OF LOW MOLECULAR WEIGHT HEPARIN: AN IN VITRO STUDY.HEART,96,
MLA：
Shi Xu-Bo,et al."THE SENSITIVITY OF NEW REAGENTS FOR LABORATORY MONITORING OF LOW MOLECULAR WEIGHT HEPARIN: AN IN VITRO STUDY".HEART 96.(2010):A55-A55
医学